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1Chapter
The Role of Th17 Cells in the 
Pathogenesis of Behçet’s Disease
Yuki Nanke and Shigeru Kotake
Abstract
Behçet’s disease (BD) is a polysymptomatic and recurrent systemic vasculitis 
with a chronic course and unknown cause. BD is now categorized as both autoim-
mune diseases and auto inflammatory diseases. The pathogenesis of BD is still 
unclear; however, BD has been thought as a Th1-related disease, with elevating 
levels of Th1 cytokines such as IFN-γ, TNF-α, and IL-2. Some investigators found 
that Th17-associated cytokines were elevated in patients with BD; thus, IL-17/IL-23 
pathway and Th17 cells may have crucial roles in the pathogenesis of BD. In this 
chapter, we review the pathogenic role of Th17 cells in BD.
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1. Introduction
BD is a systemic vasculitis and polysymptomatic [1, 2] and characterized by 
recurrent aphthous stomatitis, genital ulcers, uveitis, and skin lesions. Arthritis is 
also a common manifestation of BD, and sometimes inflammation is involved in the 
gastrointestinal tract as well as vascular and central nervous systems. The cause of 
BD is not fully understood. BD is now categorized as both an autoimmune disease 
and an autoinflammatory disease.
The association between carriage of the human leukocyte antigen (HLA) B51 
allele and BD has been known in different ethnic groups. Recently, the genome-
wide studies showed the association of some non-histocompatibility complex 
(MHC) genes, including IL-23R-IL-12 RB 2 and IL-10 genes [3, 4]. The pathogen-
esis of BD has not been fully elucidated; in addition to genetic factors, cytokines, 
viral and bacterial agents, and immune dysfunction are associated with the exacer-
bation of BD.
CD4+ T cells and neutrophils play an important role in the pathogenesis of 
BD. Since IL-12 and IFN-γ from Th1 cells can mediate the inflammatory response 
between neutrophils and T cells, BD has been considered as a Th1-mediated 
disease [5, 6].
Th17 cells play an important role in immunity. Th17 cell differentiation from 
naïve CD4+ T cells is assisted by IL-6, IL-21, IL-1β, and IL-23. The critical feature 
of Th17 cells is the expression of IL-17A, IL-17F, IL-22, IL-6, IL-8, and IL-26, and 
TNF-α expresses RAR-related orphan receptor (ROR) γ. The current studies suggest 
that Th17 axis plays a pivotal role in BD pathogenesis. IL-17 has been shown to 
recruit neutrophils to the site of inflammation. Abnormalities in the T cell response 
cause the hyperreactivity of neutrophils in BD through the production of cytokines, 
such as IL-17 [7]. We discuss the pathogenic role of Th17 cells in BD.
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2. Th17 in mouse model
In mice, the combination of IL-6 and TGF-β plays a critical role in the devel-
opment of Th17 cells from naive T cells. Th17 cells play important roles in the 
pathogenesis of intraocular inflammation in an animal model of uveitis [8–10]. 
Anti-mouse IL-17 blocking antibodies are effective for intraocular inflammation in 
experimental models of uveitis [11].
Inhibition of the expression of TNF-α [12], and the downregulation of IL-6 [13] 
improved the inflammation in BD mice by the upregulation of Th17 cells. Foxp3 
may inhibit Th17 differentiation by antagonizing the function of RORγt, the master 
transcription factor. It is reported that anti-TNF-α blockade may prevent the dif-
ferentiation of Th17 cells in animal models for BD [14]. γδ T cells produce IL-17 and 
may play an important role in experimental uveitis in animal models [10].
3. Th17 in humans
3.1 Plasma IL-17 levels in BD
In humans, IL-23 and IL-1β are needed for the development of Th17 cells. IL-17 
levels were markedly elevated in BD [15–20]. Some investigators [22, 23] reported 
that the ability to produce IL-17A and amount of circulating Th17 cells were 
increased in active BD patients. Increased levels of IL-17 may induce neutrophil 
activity [22].
It is reported that the ability to produce IL-17A and population of Th17 cells are 
enhanced in active BD despite the low expression of RORγt mRNA [21]. Chi et al. 
reported that elevated levels of IL-17A, IL-23, and IFN-γ in the aqueous fluid from 
the eyes as well as in peripheral blood of BD patients [23, 24].
3.2 Circulating Th17 cell frequencies are correlated with disease activity
It is reported that the significantly higher frequency of circulating Th17 cells are 
detected in active BD patients compared with the same patients in remission stages 
[21]. A positive correlation was seen between the plasma IL-17 level and ESR or CRP 
in active BD patients [21]. It has been reported that the peripheral blood Th17/Th1 
ratio was markedly higher in patients with active BD than the healthy controls [25, 
26] and that in BD patients with folliculitis or uveitis, the Th17/Th1 ratio was elevated 
[23, 24]. Thus, the balance of Th1 and Th17 cells plays an important role in the patho-
genesis of BD, especially in the pathogenesis of folliculitis and uveitis. Moreover, the 
high expression of IL-23p19 mRNA was detected in the erythema nodosum (EN)-like 
lesion of BD [27].
A significant increase in IL-17- and IFN-γ-expressing CD4+ memory T cells was 
observed in patients with active BD compared with control groups [28]. Similarly, 
the levels of IL-17, IL-23, IL-12/IL-23p40, and IFN-γ in serum and supernatants 
were increased in active BD patients compared with control groups [28]. IFN-γ-
secreting Th17 cells were elevated in BD patients [27–29]. Touzot M et al. reported 
that IL-17 was not inhibited by IFN-α in BD and IFN-α increased IFN-γ level in 
memory CD4+ T cells in BD [31]. Thus, BD is associated with a mixture of TH1/
Th17 cytokine.
Patients with BD in remission expressed low Th17 levels compared to active BD 
[21, 24, 28]. Thus, the population of Th17 cells is correlated with BD activity [16, 22].
More recently, Lucherini et al. [32] reported that serum amyloid A (SAA) 
induced Th17 polarization rather than Th1 differentiation from CD4+ T cells in BD 
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patients. A critical regulation of Th17 may be the functional link between acute SAA 
increase and the induction of Th17-mediated inflammatory response in BD.
Deniz et al. [33] reported that under Th17-stimulating conditions, T cells express 
both IL-17 and IFN-γ in BD. In addition, they speculated that more prominent IL-17 
and IFN-γ production by all lymphocyte subsets in BD may be associated with the 
increased innate responses, early tissue neutrophil infiltrations, and late adaptive 
immunity in BD.
3.3 IL-23-IL-17 axis
Recently, it is reported that IL-23R is principal for the differentiation of 
IL-17-producing effector T cells in vivo [34]. IL-23 was essential to preserve and 
to generate Th17 cells even in the absence of TGF-β [35]. The IL-23-IL-17 axis is 
crucial for the inflammation in BD [23]. Elevated levels of IL-23 and IL-17 [21, 28] 
were seen in peripheral blood mononuclear cells (PBMC) from active BD patients 
[23]. Recombinant IL-23 stimulated IL-17 in CD4+ T cells in BD patients [15, 23]. 
Recently, IL-23R, IL-12RB2, and IL-10 were identified as BD susceptibility loci by 
genetic surveys including GWAS [3, 4]. It is reported that the genetic variation of 
IL-17F and IL-23 A is associated with BD [36]. Jiang et al. [37] reported that IL-23R 
gene polymorphism enhanced the expression of the IL-23 R and IL-17 in BD patients.
3.4 The suppressive effect of IL-27 on Th17 cell differentiation
IL-27 is a regulator of the proinflammatory T cell response. In mouse, IL-27 plays a 
negative role in Th17 cell differentiation. It is reported that decreased level of IL-27 in 
patients with active BD [38] and decreased IL-27 expression was correlated with uve-
itis activity in patients with BD [38]. IL-27 inhibited human Th17 cell differentiation 
by upregulation of the expression of interferon regulatory factor (IRF) 8 [38]. Previous 
studies have shown that the presence of IL-27 limits Th17-mediated uveitis [39].
4. IL-21 and IL-26 in BD
It was reported that the expression of IL-21 was elevated in the serum of active 
BD patiens, and that this promoted Th17 differentiation [16]. IL-26 levels in 
cerebrospinal fluid and bronchoalveolar lavage fluid in BD patients showed positive 
correlations with IL-17 level. IL-26-stimulated CD4+ T cells and monocytes promote 
the generation of Th17 and suppress regulatory T cell cytokines [40].
5. Uveitis in BD
Some investigators reported that IL-17 [15, 41], IL-23, and IFN-γ in the sera and 
aqueous humor significantly increased in BD patients with active uveitis compared 
with BD patients without active uveitis and HC [23]. It is also reported that IFN-γ-
producing and IL-17-producing T cells in BD patients with active uveitis were increased 
[15, 23, 38]. Thus, the IL-23/IL-17 pathway plays an important role in active uveitis in BD 
patients. Activated CD4+ T cells obtained from BD patients produce TNF-α in vitro. Chi 
et al. demonstrated that IL-12 exerted its inhibitory effect on IL-17 through IFN-γ. They 
also reported that recombinant-IL-23 (rIL-23) can promote the production of IL-17 by 
CD4+ T cells in BD patients [23]. Jiang et al. reported an association of rs17375018 in the 
IL-23R gene with uveitis in BD patients [41]. Taken together, elevated levels of IL-17 may 
be associated with the intraocular inflammation of BD patients [15, 23].
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6. Oral and genital ulcer and articular symptoms
Alpsoy et al. reported that IL-17 levels of BD patients with active stages of oral 
and genial ulcers and articular symptoms were higher than BD patients with inac-
tive stages of these symptoms [42]. They also found that the percentage of CD4+ 
IL-17+, IL-17, and CD4− IL-17+ T cells was significantly elevated after E. coli and 
PHA stimulation in active organ involvement.
7. Skin
Hamzaoui et al. confirmed that the presence of an important population of IL-17+ 
cells infiltrates the erythema nodosum-like eruption in BD skin lesions using antibod-
ies to IL-17A [21]. Shimizu et al. demonstrated that IFN-γ + IL-17 + -producing cells 
were dominant, and some of them were CD4+ cells in BD-EN compared with healthy 
controls [30]. Th17 cells are elevated in circulation and distribution over the skin lesions 
of BD patient. Ekinci et al. reported that serum IL-17A levels were markedly elevated 
in BD patients with active stages of oral ulcers or genital ulcers compared with inactive 
stage of these symptoms [22]. They also studied the proportion of IL-17-secreting cells 
in patients with active organ involvement, showing that the percentage of IL-17, CD4− 
IL-17+ cells, and CD4+ IL-17+ cells was significantly elevated [20, 22]. This finding indi-
cated that Th17 and IL-17 pathway has a crucial role in the acute attack of the disease.
8. Entero-BD
Gastrointestinal involvement is an important complication of BD. Emmi et al. 
[43] found that T cells at the intestinal mucosal level produce a high amount of 
TNF-α and in the early stage of BD. Both Th17 and Th1 cells drive inflammation 
and mucosal damage though long-lasting cytokine production [44]. Imamura et al. 
reported the infiltration of CD4+ and CD8+ T cells in the intestine of BD patient, 
like the expression of mRNAs of proinflammatory and Th1 cytokines/chemokines 
[45]. Recently, IL-17A, IL-23R, and STAT4 polymorphisms may be involved in the 
pathogenesis of intestinal involvement in Korean BD patients [46]. On the other 
hand, Ferrante et al. reported that the serum and mRNA level of IL-23 and IL-17 in 
entero-BD were not different from those with control groups; thus a Th1 but not a 
Th17 response occurs with entero-BD [47]. More studies are needed to reveal the 
role of IL-17 in intestinal involvement of BD.
9. Neuro-BD
The expression of RAR-related orphan receptor C (RORC), which is the master 
transcription factor of Th17 cells, was elevated in the cerebrospinal fluid (CSF) of 
patients with neuro-BD [48]. In the CSF, the Th17/regulatory T cell (Treg) ratio 
was elevated [49]. It was reported that increased level of IL-17 secretion in the sera 
of BD patients and the elevated expression of transcription factors for Th17 cells 
were shown in the CSF were detected with neuro-BD patients [48]. It is reported 
that IL-17A- and IL-21-producing T cells in the CSF, brain parenchyma inflamma-
tory infiltrates, and intra-cerebral blood vessels from patients with active BD and 
neuro-BD [16]. The stimulation of CD4+ T cells with IL-21 increased Th1 and Th17 
differentiation and decreased the regulatory T cells [16]. Conversely, IL-21 blockade 
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with an IL21R-Fc restored the Th17 and regulatory T cell homeostasis in BD patients 
[16]. On the other hand, Saruhan-Direskeneli et al. [49] reported that, both in 
serum and the CSF, IL-17 was not detectable in BD patients with CNS involvement. 
Thus, the pathogenesis of IL-17 in neuro-BD remains controversial.
10. Polymorphisms
The signaling molecules and Th1- and Th17-related cytokines are involved in the 
pathogenesis of BD [50–52]. Several reports showed that polymorphisms of Th17-
related cytokines and receptors, such as IL-17F, IL-23R, and IL-23 A, were related 
to BD susceptibility in Korean and Chinese [41, 53, 54]. STAT4 is necessary for the 
increase of Th17 cells activated by IL-23. Functional studies showed that the risk SNPs 
in the STAT4 gene took part in BD might affect the expression of STAT4 and produc-
tion of IL-17 [55]. The haplotype of IL-17A had a relation to the entero-BD risk, where 
those of IL-23R are protected against disease expansion. The interactions of IL-23R, 
IL-17A, and STAT4 SNPs modify the susceptibility to intestinal BD, suggesting the 
crucial role of the IL-17/IL-23 axis in the pathogenesis of intestinal BD [56].
11. Plasticity
Recently, plasticity of Th17 and Th17 cells means that they can produce Th1 (IFN-
γ)- or Th2 (IL-4)-type cytokines under inflammation [57, 58]. Th17 cells are able to 
change IFN-γ-expressing T cells in mouse Th1 disease models, which are named Th17/
Th1 cells, IFN-γ-expressing Th17 cells, or Th1-like cells. The expression of RORC is not 
fixed in T cells, and the plasticity of Th17 cells was recognized in murine models in vivo 
[45]; this conception was applied to human diseases [59, 60]. Geri et al. demonstrated 
that the frequencies of IFN-γ CD4+ T cells and IL-17+ CD4+ T cells were increased 
in the CSF than in PBMC in BD patients [16]. Th1 and Th17 cells may be complicated 
at different steps in inflammatory process, and more Th17 cells were generated than 
Th1 cells during the inflammatory process. The elevated level in Th17/Treg cells and 
Th17/Th1 ratios is correlated with the expanse of inflammation. In BD, plasticity exists 
between Th1, Th17, and Treg cells during inflammation at inflammatory sites and in 
the peripheral circulation [61]. The low levels of Th17 in remission BD compared with 
active BD may be due to a conversion of Th17 cells into Treg cells. The differentiation 
of Treg cells into Th17 cells was involved in the downregulation of FoxP3 expression 
and the suppressor function. Foxp3 inhibits Th17 differentiation by antagonizing the 
RORγt function [62]. Sonmez et al. [63] reported that IL-17A/F levels increased parallel 
to IL-23 levels in BD and IL-35 levels were lower in active BD patients than the inactive 
BD patients, which may be a plasticity between Th17 and Treg cells according to the 
state of disease activity.
12. Therapy
12.1 Cyclosporine A (CsA)
CsA is effective for reducing the severity of intraocular inflammation of BD. Chi 
et al. reported that CsA has an effect on both IFN-γ and IL-17 productions in vitro 
and in vivo. In vitro, it was shown that CsA inhibited IL-17 production from PBMC 
of BD patients. In vivo, the improvement of intraocular inflammation in BD was 
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accompanied by the suppression of both IFN-γ and IL-17 productions after CsA 
administration [24]. Therefore, it is suggested that the efficacy of CsA on uveitis in 
BD is through the inhibition of IFN-γ and IL-17 production.
12.2 Antibodies to IFN-α
Type I IFNs were able to inhibit IL-17 production by PBMC. Recombinant 
IFN-α has been used to treat BD [57]. Liu et al. reported that significantly higher 
levels of IL-17 are detected in active BD patients and stimulation with IFN-α 
decrease IL-17 production [17]. In vitro study showed that IFN-α does not directly 
regulate the Th1/Th17 balance in BD but rather promotes a regulatory Th1 response 
through IL-10 secretion [63]. IFN-α activity was mediated via STAT2 phosphoryla-
tion [17]. IFN-α upregulates the gene expression of IL-27, a negative regulator of 
Th17 cells [64].
12.3 Anti-TNF-α therapy
TNF-α has been detected in patients with BD [5]. Anti-TNF-α blockade can 
increase Tregs [46] and prevent effector T cell differentiation in BD patients 
with uveitis [14, 65, 66]. It was demonstrated that the production of IL-17 by 
polarized Th17 cell lines exposed to infliximab in vitro or fresh CD4+ T cells 
from BD patients being treated with infliximab was decreased and the RORγt 
in T cells was also decreased. Therefore, TNF-α is needed for Th17 differentia-
tion in BD. CD4+ T cells exposed to anti-TNF-α blockade may transform into 
Treg cells. Anti-TNF-α therapy-induced Treg cells from BD patients restrained 
the activation of target T cells [14]. Anti-TNF-α agents have efficacy for uveitis, 
neurological and gastrointestinal involvement, and vessel diseases in BD [66]. 
Taken together, the Th17/Treg cell balance may be crucial for the inflammation 
in BD [45, 58].
12.4 Antibodies to IL-17A
IL-17A has a crucial role in deterioration of eye disease and oral ulcers, genital 
ulcers, and articular symptoms [21–23]. IL-17A from active BD patients can increase 
the expression of adhesion molecule mRNA. Therapy with antibodies to IL-17A 
decreased the production of adhesion molecules [21, 67]. Some reported [68–70] 
that secukinumab improved active mucocutaneous manifestation refractory to 
previous treatment such as colchicine, conventional DMARDs, and anti-TNF-α 
agent [69], and refractory oral ulcers [68]. Thus, therapeutic modalities attempting 
to evaluate new approaches to eliminate the over activities of IL-17A and/or the 
IL-23/IL-17 pathway may clarify the pathological importance of Il-17A and Th17 
cells in BD patients.
13. Other therapeutic strategies
It is reported that suppression of microRNA-155 reduced the amount of patho-
genic IL-17-expressing T cells [71].
13.1 Prognostic biomarker
The proportion of Th17 cells was increased, which was related with the increas-
ing levels of IL-17, IL-23, and RORγt mRNA expression in BD patients. Ahmadi 
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et al. [72] reported that T cell-associated miRNA expression levels, miR-25, 
miR-106b, miR-326, and miR-93 were significantly unregulated in PBMCs in BD 
patients; thus the evaluation of immune cells and related miRNA profile may serve 
as prognostic biomarker.
14. Conclusion
BD is predominated by Th1 and Th17 immune responses. Th17 cells are associ-
ated with the active inflammation of BD. Thus, IL-23-IL-17 axis and Th1/Th17-type 
immune responses are crucial for inflammation and have a pathologic role in BD.
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